When it comes to NVDA… “acceleration cycles” are the key

Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.

Use this link to see Nvidia Unchained right away!

Dean Li Biography and Net Worth

Director of Recursion Pharmaceuticals

Dean is the President at Merck Research Laboratories. He has served as VP of Translational Medicine or in other roles at Merck since 2017. Prior to his move to the large pharmaceutical company, Dean was on the cutting-edge of translational medical research at the University of Utah for more than two decades. During his time at the university, he co-founded multiple biotech companies stemming from research from his laboratory, including Recursion, Hydra Biosciences and Navigen Pharmaceuticals. Dean served as the H.A. & Edna Benning Professor of Medicine and Cardiology, the vice-dean of research at the University of Utah Health Science Center, and as the chief scientific officer of University of Utah Health Care. Dean also served as interim CEO of Associated Regional University Pathologists (ARUP), the nation's third-largest clinical reference laboratory, from 2015 to 2016. Dean trained at Washington University in Saint Louis before coming to Utah to work as a post-doc in the laboratory of Mark Keating.

What is Dean Y. Li's net worth?: The estimated net worth of Dean Y. Li is at least $2.54 million as of January 9th, 2024. Dr. Li owns 421,000 shares of Recursion Pharmaceuticals stock worth more than $2,542,840 as of November 21st. This net worth evaluation does not reflect any other assets that Dr. Li may own. Learn More about Dean Y. Li's net worth.
How do I contact Dean Y. Li?: The corporate mailing address for Dr. Li and other Recursion Pharmaceuticals executives is 41S RIO GRANDE STREET, SALT LAKE CITY UT, 84101. Recursion Pharmaceuticals can also be reached via phone at 385-269-0203 and via email at [email protected]. Learn More on Dean Y. Li's contact information.
Has Dean Y. Li been buying or selling shares of Recursion Pharmaceuticals?: Dean Y. Li has not been actively trading shares of Recursion Pharmaceuticals in the last ninety days. Most recently, Dean Y. Li sold 29,000 shares of the business's stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $13.66, for a transaction totalling $396,140.00. Following the completion of the sale, the director now directly owns 421,000 shares of the company's stock, valued at $5,750,860. Learn More on Dean Y. Li's trading history.
Who are Recursion Pharmaceuticals' active insiders?: Recursion Pharmaceuticals' insider roster includes Blake Borgeson (Director), Terry-Ann Burrell (Director), Zavain Dar (Director), Christopher Gibson (CEO), Tina Larson (COO), Dean Li (Director), Michael Secora (CFO), and Shafique Virani (Chief Corporate Development Officer). Learn More on Recursion Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Recursion Pharmaceuticals?: In the last year, insiders at the sold shares 61 times. They sold a total of 1,151,301 shares worth more than $10,096,309.56. The most recent insider tranaction occured on November, 13th when CFO Michael Secora sold 15,000 shares worth more than $114,900.00. Insiders at Recursion Pharmaceuticals own 15.8% of the company. Learn More about insider trades at Recursion Pharmaceuticals.
Information on this page was last updated on 11/13/2024.

Dean Y. Li Insider Trading History at Recursion Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/9/2024	Sell	29,000	$13.66	$396,140.00	421,000
11/19/2021	Sell	13,474	$20.20	$272,174.80
11/17/2021	Sell	5,626	$20.04	$112,745.04

Dean Y. Li Buying and Selling Activity at Recursion Pharmaceuticals

Recursion Pharmaceuticals Company Overview

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Today's Range

Now: $6.04

$5.70

$6.37

50 Day Range

MA: $6.65

$6.04

$7.84

2 Week Range

Now: $6.04

$5.70

$15.74

Volume

16,994,717 shs

Average Volume

6,194,816 shs

Market Capitalization

$1.73 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.81